MDMelike Karaçam Doğan

Melike Karaçam Doğan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melike Karaçam Doğan has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in the effect of childhood adversity and coping strategies on psychosis expression: A TwinssCan study

    by Melike Karaçam Doğan, Thanavadee Prachason, Laura Fusar-Poli, Claudia Menne-Lothmann, Jeroen Decoster, Ruud van Winkel, Dina Collip, Philippe Delespaul, Marc De Hert, Catherine Derom, et al.

    Background: Sex differences in psychosis pathoetiology are insufficiently understood. This study explores how childhood adversity (CA) and coping mechanisms relate to psychosis expression (PE) across males and females in the general population. Methods: Data from the TwinssCan project (males: n = 312; females: n = 478) were used. The Childhood Trauma Questionnaire assessed CA domains. The Utrecht Coping List assessed coping strategies. Psychosis expression was assessed using the Community Assessment of Psychic Experiences (CAPE). Mixed linear regression analyses examined sex-stratified associations of CAPE scores with CA, coping strategies, and their interactions. Results: Emotional abuse (EA) was associated with increased total CAPE scores (T-CAPE), explaining the greatest variance among CA across sexes. Sex-specific effects showed that sexual abuse (SA) and physical abuse (PA) were linked to higher T-CAPE in females, whereas physical neglect (PN) was linked to higher T-CAPE in males. Passive-reacting was associated with increased T-CAPE, explaining the greatest variance among coping styles across both sexes. Sex-specific effects showed that, in females, seeking social support was linked to decreased T-CAPE, while emotional expression increased it. The only sex-shared interaction effect was between reassuring thoughts and emotional neglect (EN), associated with decreased T-CAPE. In females, social support (× PA/PN/EA), reassuring thoughts (× PA/PN), and palliative-reacting (× PN/PA) were associated with decreased T-CAPE, while passive-reacting (× EN) increased it. In males, avoidance (× SA/PA) and passive-reacting (× PN) were associated with increased T-CAPE. Conclusions: Sex differences in the associations of PE with CA and coping underscore the necessity for sex-specific interventions that promote adaptive coping strategies.


  • Open Access

    Mapping the Exposome of Mental Health Outcomes to Enhance Population Salutogenesis

    by Melike Karaçam Doğan, Sinan Guloksuz


  • Open Access

    The transfer process from child and adolescent mental health services to adult mental health services for patients with childhood-onset neurodevelopmental disorders: first case–control study from Türkiye

    by Melike Karaçam Doğan, Yağmur Karakuş Aydos, Şükrü Keleş, Halime Tuna Çak Esen, Mevhibe İrEm Yildiz

    Background: The transfer from child and adolescent mental health services (CAMHS) to adult mental health services (AMHS) can be challenging, particularly for adolescents with neurodevelopmental disorders (NDDs) requiring long-term follow-up. Aims: To examine the transfer process from CAMHS to AMHS in a university hospital in Türkiye, focusing on challenges, service gaps and barriers to transfer for individuals with NDDs. Method: Hospital records of children with NDDs followed in CAMHS for at least 5 years were reviewed. Children with at least one annual admission until 2017–2018 were included. A total of 211 patients were categorised into two groups: those who transferred to AMHS by 2018–2019 (transferred group, 81 patients) and those who did not transfer (non-transferred group, 130 patients). Clinical features, such as primary diagnosis and treatments, were compared, and parental views on the transfer process were collected via telephone interviews. Results: The transferred group included 81 patients (38.4%), whereas the non-transferred group had 130 patients (61.6%). Of the total sample, 55 (26.1%) were female, and 156 (73.9%) were male. Primary diagnoses were similar between groups; however, the transferred group had more comorbidities (P < 0.001) and more frequent antipsychotic prescriptions (P = 0.006). Proactive information from CAMHS doctors (B = 2.46, s.e. = 0.68, P < 0.001) and psychiatric comorbidities predicted transfer. In addition, attention-deficit hyperactivity disorder diagnoses changed during transfer in the transferred group (P = 0.002). Conclusion: These findings emphasise the need for tailored transition support to enhance mental healthcare for NDD patients and indicate areas where further research is required to address healthcare barriers.


  • Effects of Clozapine on Cortical Inhibition

    by Melike Karaçam Doğan, Fatma Gökçem Yildiz, Çağri Mesut Temuçin, Aygün Ertuğrul

    Background: Preclinical and clinical investigations have revealed deficits in cortical inhibition in individuals with schizophrenia. Transcranial magnetic stimulation, a commonly used noninvasive measurement technique, is used for assessing these deficits. Limited research has been conducted on the effects of antipsychotic medications on cortical inhibition. This study aimed to evaluate the effects of clozapine on cortical inhibition with transcranial magnetic stimulation longitudinally and compare it with unaffected controls. Methods: Ten patients who started clozapine were assessed at baseline, with 8 reassessed after 4 months. Eight age- and sex-matched unaffected controls were included. Psychopathology, neurocognitive performance, formal thought disorder, and disability were assessed, and the cortical excitability parameters (resting motor threshold, cortical silent period, short-interval intracortical inhibition, intracortical facilitation, and short-latency afferent inhibition [SAI]) were measured at baseline and four months after clozapine treatment. Results: Resting motor threshold, ICF, and SAI were significantly different between patients and controls at baseline, whereas resting motor threshold, SAI, and ICF became similar to controls after clozapine with only ICF having a trend for significance. Clozapine prolonged cortical silent period significantly in the patients. Conclusions: This is the first study to investigate the effect of clozapine on SAI, a potential cholinergic biomarker, and the first follow-up study to investigate the relationship between the effects of clozapine on cortical inhibition and cognition. Clozapine seems to cause an increase in cortical inhibition through GABAergic and possibly cholinergic mechanisms. However, additional follow-up studies with larger sample sizes are required to reach more robust conclusions.

  • Hodgkin Lymphoma in Patients Receiving Clozapine Treatment

    by Melike Karaçam Doğan, Nilgün Oktar Erdoğan, Aygün Ertuğrul, Ayşe Elif Anil Yağcioğlu, M. Kâzim Yazici


  • Combination With Long-Acting Injectable Antipsychotics and Utilization of Nonstandard Formulations as Compliance Enhancing Methods for Clozapine Users

    by Emre Mutlu, Melike Karaçam Doğan, Aygün Ertuğrul, A. Elif Anıl Yağcıoğlu

    Background: Combining clozapine with a long-acting injectable antipsychotic (LAI) or using different, nonstandard formulations of the compound may improve treatment outcomes. We aimed to investigate the utility of the clozapine-LAI combination and different formulations of clozapine for compliance problems of clozapine treatment, and to describe a case series on the combined treatment. Procedures: We conducted a PubMed search with no date restriction. The number and length of hospitalizations, the results of clinical scales, and adverse events were recorded. We also present a case series of 18 patients using the clozapine-LAI combination. Data were collected from the medical charts and electronic records. Results: We extracted 9 records describing the use of the clozapine-LAI combination. The case reports and mirror-image studies showed a significant reduction in the number of hospitalizations, length of hospital stays, and number of visits to the emergency department on the combined treatment with no serious adverse events. We included 11 articles for clozapine formulations. The case reports and retrospective data suggested that short-acting intramuscular clozapine was often well tolerated and resulted in an increased acceptance of oral clozapine in the acute phase of illness. In our case series, illness severity and the number of hospitalization per year significantly decreased after the combined treatment, besides a significant improvement in the functioning scores. Hyperprolactinemia and extrapyramidal side effects were reported due to concomitant LAIs. Conclusions: Despite the encouraging evidence, the present data are preliminary and mostly based on retrospective studies, and oral-dissolving tablets or oral liquid formulations of clozapine have insufficient evidence for clinical practice. Well-designed, controlled, follow-up studies are needed for both clozapine-LAI combination and different formulations of clozapine.


  • Vitamin D deficiency is associated with decreased cognition independent from the disease status and AD morphology

    by Melike Karacam Dogan, Esra Özkan, Ahmet Alp Karakaşlı, Hatice Yağmur Zengin, Duygu Çap, Bedirhan Şenol, Sevilay Karahan, Ayça Karaosmanoğlu, Esen Saka, Yavuz Ayhan

    Background: 25(OH)D deficiency was associated with cognitive impairment and altered brain volumes, namely reduction in white matter and medial temporal lobe and enlargement of lateral ventricles. 25(OH)D deficiency was also associated with the development of Alzheimer's disease (AD). In this study, we aimed to investigate whether 25(OH)D levels are independently associated with cognitive performance and AD‐associated morphology in a mixed sample.Method: The study was conducted at Hacettepe University Faculty of Medicine, Ankara, Turkey. The participants were chosen from our dementia research database.Demographic variables, 25(OH)D levels, standardized Modified Mini Mental Test (3MS) z‐scores, 1.5 T brain MRI, the data for comorbid medical conditions and current prescription drugs were used as pertinent variables. FreeSurfer v.6.0 was used for automated structural neuroimaging analysis. Based on the previous literature, AD cortical signature, predictive cortical thickness, medial temporal lobe gray matter and mean hippocampal volumes were calculated and used independently to assess AD‐related morphological changes. Cut‐off for 25(OH)D deficiency was accepted as 20 ng/ml. Statistical analyses were conducted using IBM SPSS Statistics 23 for Windows. To assess the predictive power of 25(OH)D, regression models were used with standardized 3MS scores and AD‐related areas as dependent variables. Statistical assumptions were met for all models presented. Funded by TUBITAK 214S048 and Hacettepe University THD 2018‐17363.Result: A total of 210 patients over 55 years of age (47 AD, 15 nonAD dementia, 74 Mild and Subjective Cognitive Impairment, 74 cognitively intact) were included. Mean 25(OH) level was 22.48 ±15.8 ng/ml. 108 participants (51.4%) had 25(OH)D deficiency (AD 57%, nonAD Dementia 60%, SCI/MCI 51%, Control 46%, p>0.5). 25(OH)D deficiency was significantly associated with 3MS scores (χ2 =5.608,df=1,p=0.018). The association was also marginally significant when adjusted for age, diagnosis and medial temporal lobe gray matter volume (Exp(β): 2.472, p=0.05). 25(OH)D levels were not associated with AD‐related morphological changes on multivariate analyses.Conclusion: Plasma 25(OH)D levels are associated with cognitive performance regardless of the diagnosis. The effect seems to be independent of AD‐related brain morphological changes. Our results suggest an independent effect of 25(OH)D levels on cognition.